Clinical trials: Rivaroxaban
Clinical Pharmacology
Study to Compare the Effect of the Formulations (Orally Disintegrating Tablet and Film-coated Tablet) on Bioequivalence of Drug Rivaroxaban (Xarelto) at Dose of 10 mg in Japanese Healthy Male Adult Subjects
Researchers in this study wanted to compare the effect of the formulation (orally disintegrating tablet and film-coated tablet) on the bioequivalence of drug Rivaroxaban (brand name: Xarelto) at dose of 10 mg in Japanese healthy…
- Trial name
- NCT04511611
- Testing
- Rivaroxaban (BAY 59-7939, Xarelto) in ODT form, Rivaroxaban (BAY 59-7939, Xarelto) in film-coated form
- Where
- 3 sites in Japan
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Bayer
Pharmacokinetics
Relative Bioavailability Study in Healthy Subjects Comparing 2 Dry Powder Oral Suspensions of Rivaroxaban Under Fasting and 20 mg of an Oral Suspension of Rivaroxaban Under Fed Conditions to 10 mg of an Immediate Release Tablet Under Fasting Conditions
Rivaroxaban is a substance developed for use in the treatment of blood coagulation disorders.Thrombosis (blood clots) can occur as a result of excessive coagulation activity in the blood vessels.
- Trial name
- NCT02367027
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- Germany
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Bayer
Blood Clot
A Prospective Pharmacodynamic Study of Rivaroxaban
The ability to explain bleeding or clotting complications in patients treated with rivaroxaban remains challenging. In addition, there is limited data on how coagulation tests perform in patients treated with therapeutic doses of…
- Trial name
- NCT01743898
- Testing
- Rivaroxaban, no anticoagulation
- Where
- United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Thrombosis, Anticoagulant-induced Bleeding
Reversal of the Antithrombotic Action of New Oral Anticoagulants
The main goal of this study is to improve safety and efficiency of clinical practice with the new generation of oral anticoagulants. 1.
- Conditions
- Thrombosis, Anticoagulant-induced Bleeding, Anticoagulant Overdosage, Hemorrhage
- Trial name
- REVANT (NCT01478282)
- Testing
- Rivaroxaban, Dabigatran
- Where
- Spain
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Gines Escolar
Pharmacokinetics, Bioavailability
Pharmacokinetics Study of Oral Rivaroxaban in Healthy Participants
The primary objective of this study is to learn about the relative bioavailability (the extent to which the drug becomes available to the body) and pharmacokinetics (blood levels) of rivaroxaban in healthy participants after…
- Conditions
- Pharmacokinetics, Bioavailability, Healthy Participants
- Trial name
- NCT01464450
- Testing
- Rivaroxaban
- Where
- United States
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Janssen Scientific Affairs, LLC
Bleeding
A Study in Older Subject to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Rivaroxaban
The purpose of this study is to evaluate the ability of Andexanet Alfa to reverse the anticoagulation effect of Rivaroxaban.
- Trial name
- NCT02220725
- Testing
- Andexanet
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Portola Pharmaceuticals
Healthy Volunteers
A Trial to Learn How Much Rivaroxaban Gets Into the Blood When Taken in Different Forms and How Safe They Are in Healthy Men
Researchers are looking for a better way to treat venous thromboembolic disease, also known as VTE. In people with VTE, blood clots form in the veins of the legs, groin, or arms.
- Trial name
- NCT04727021
- Testing
- 20 mg tablet rivaroxaban, 20 mg rivaroxaban, granules for oral suspension
- Where
- Germany
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Bayer
Biological Availability
Relative Bioavailability of Oral Suspension of Rivaroxaban Compared to Standard Tablet
Rivaroxaban is a substance developed for use in the treatment of blood coagulation disorders. Thrombosis (blood clots) can occur as a result of excessive coagulation activity in the blood vessels.
- Trial name
- NCT01853800
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- Germany
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Bayer
Healthy
Bioequivalence Study of Rivaroxaban From Repatoxaban 10 mg Tablets (Horus for Pharmaceutical Industries, Egypt) and Xarelto® 10 mg Tablets (Janssen Pharm., Licensed From: Bayer Healthcare, Germany)
An open label randomized, single dose, two-way crossover bioequivalence study to determine the bioequivalence of Rivaroxaban from Repatoxaban 10 mg Tablets (Horus for Pharmaceutical Industries, Egypt) and Xarelto® 10 mg Tablets…
- Trial name
- NCT03071380
- Testing
- Repatoxaban, Xarelto
- Where
- Egypt
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Genuine Research Center, Egypt
Healthy
Rivaroxaban Laboratory Monitoring in Switzerland 2: Therapeutic Dose (RivaMoS 2)
Rivaroxaban (RXA; brand name Xarelto®) is an oral direct factor Xa inhibitor that is applied for prophylaxis of venous thromboembolism after major orthopedic surgery.
- Trial name
- RivaMoS2 (NCT01710267)
- Where
- Switzerland
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Prof. Dr. Dr. med. Walter A. Wuillemin, MD, PhD
Embolism, Atrial Fibrillation and Venous Thrombosis
Bioequivalence Study of Rivaroxaban in Japanese Healthy Adult Male Subjects
The objectives of this study are to establish the bioequivalence between rivaroxaban tablet 10mg and rivaroxaban granule formulation 10mg, and to assess the safety and tolerability of rivaroxaban 10mg in healthy adult male…
- Trial name
- NCT02537405
- Testing
- Rivaroxaban (BAY 59-7939), Rivaroxaban (Xarelto, BAY 59-7939)
- Where
- Japan
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Bayer
Healthy
Non Inferiority Study of a Reduced Dose of Activated Charcoal on Rivaroxaban Pharmacokinetics.
Rivaroxaban is a direct oral anticoagulant that target specifically activated factor X. Bleeding events related to rivaroxaban are the consequence of physiopathologic, pharmacokinetic issues or poisoning.
- Trial name
- RICHAR2 (NCT04767776)
- Testing
- Rivaroxaban, Activated charcoal
- Where
- France
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Used in Patients Receiving Anticoagulant Therapy (e.g., Rivaroxaban or Apixaban, Inhibitors of Coagulation Factor Xa) Who Require Reversal of Anticoagulation
Phase I Study of MT1011 Injection in Healthy Subjects
This is a single-center, randomized,double-blind, placebo-controlled Phase I study to evaluate safety, PK and PD of single ascending dose (SAD) of MT1011 injection in healthy adult subjects.
- Trial name
- NCT07024160
- Testing
- MT1011
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Shaanxi Micot Pharmaceutical Technology Co., Ltd.
Anticoagulant Therapy
Pharmacokinetics and Point of Care Testing of Direct Oral Anticoagulants Subjects
DOACs are increasingly used since 8 years. Standard coagulation tests (Prothrombin time [PT] and activated partial thromboplastin time [aPTT]) from plasma samples show a high variation.
- Trial name
- PHAPOCU (NCT05491460)
- Testing
- Apixaban 5 MG Tab, Dabigatran 150 MG Tab, Edoxaban 60Mg Tab
- Where
- Germany
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Doasense GmbH
Drug Drug Interaction Study
Rivaroxaban Sotorasib Interaction Study
Venous thromboembolic Events (VTEs) are common in lung cancer patients with an incidence of >15%, requiring anticoagulant treatment or prophylaxis.
- Trial name
- ROSIE (NCT06314763)
- Testing
- Rivaroxaban 20mg, Sotorasib 960mg
- Where
- Netherlands
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Combined Anticoagulation and Antithrombotic Therapy, PAD - Peripheral Arterial Disease
Effectiveness of Combined Anticoagulation and Antithrombotic Therapy vs Antithrombotic Therapy Alone After Lower Extremity Revascularization for Peripheral Arterial Disease
EFFECTIVENESS OF COMBINED ANTICOAGULATION AND ANTITHROMBOTIC THERAPY VS ANTITHROMBOTIC THERAPY ALONE AFTER LOWER EXTREMITY REVASCULARIZATION FOR PERIPHERAL ARTERIAL DISEASE.
- Trial name
- NCT04994223
- Testing
- Rivaroxaban 10 MG Oral Tablet [Xarelto]
- Where
- Pakistan
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Armed Forces Post Graduate Medical Institute (AFPGMI), Rawalpindi
Gastric Bypass Status
Rivaroxaban Effects in Subjects Who Have Undergone Gastric Bypass Surgery
The investigators are attempting to compare the anticoagulant (blood thinning) effects of a recently FDA approved medication, Rivaroxaban, in people who have undergone gastric bypass surgery to people who have not had this…
- Trial name
- NCT02058199
- Testing
- rivaroxaban
- Where
- United States
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- State University of New York - Upstate Medical University
Thromboembolic Disorders
A Trial to Learn How a New Liquid Form of Rivaroxaban Behaves and How Safe it is Compared to the Current Tablet Form of Rivaroxaban in Healthy Male Participants
Researchers were looking for another way to treat people with a blood clot in their veins. Before a treatment can be approved for people to take, researchers do clinical trials to better understand its safety and how it behaves.
- Trial name
- NCT04720092
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- Germany
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Bayer
Embolism, Atrial Fibrillation and Venous Thrombosis
Bioequivalence Study of Rivaroxaban
The objectives of this study are to establish the bioequivalence between rivaroxaban tablet 15 mg and rivaroxaban granule formulation 15 mg, and to assess the safety and tolerability of rivaroxaban 15 mg in healthy adult male…
- Trial name
- NCT02537457
- Testing
- Rivaroxaban (BAY 59-7939), Rivaroxaban (Xarelto, BAY 59-7939)
- Where
- Japan
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Bayer
Healthy
Study of Ciraparantag for Reversal of Anticoagulation Induced by Edoxaban, Apixaban or Rivaroxaban in Healthy Adults
A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ciraparantag for reversal of anticoagulation induced by different anticoagulant drugs in generally healthy adults as measured primarily…
- Trial name
- NCT04593784
- Testing
- Ciraparantag, Point-of-Care Coagulometer (investigational device)
- Where
- 3 sites in United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- AMAG Pharmaceuticals, Inc.